Rozita Khodashahi, Mahdieh Jajroudi, Gordon A Ferns, Mohsen Aliakbarian, Mohammad-Hassan Arjmand
{"title":"循环尿酸在胃肠道癌症中的预后价值:一项系统回顾和荟萃分析。","authors":"Rozita Khodashahi, Mahdieh Jajroudi, Gordon A Ferns, Mohsen Aliakbarian, Mohammad-Hassan Arjmand","doi":"10.22037/ghfbb.v18i1.2965","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).</p><p><strong>Background: </strong>There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.</p><p><strong>Methods: </strong>Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).</p><p><strong>Results: </strong>A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.</p><p><strong>Conclusion: </strong>Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.</p>","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"18 1","pages":"21-31"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301538/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic value of circulating uric acid in gastrointestinal cancers, a systematic review and meta-analysis.\",\"authors\":\"Rozita Khodashahi, Mahdieh Jajroudi, Gordon A Ferns, Mohsen Aliakbarian, Mohammad-Hassan Arjmand\",\"doi\":\"10.22037/ghfbb.v18i1.2965\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).</p><p><strong>Background: </strong>There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.</p><p><strong>Methods: </strong>Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).</p><p><strong>Results: </strong>A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.</p><p><strong>Conclusion: </strong>Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.</p>\",\"PeriodicalId\":12636,\"journal\":{\"name\":\"Gastroenterology and Hepatology From Bed to Bench\",\"volume\":\"18 1\",\"pages\":\"21-31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301538/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology and Hepatology From Bed to Bench\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22037/ghfbb.v18i1.2965\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology and Hepatology From Bed to Bench","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/ghfbb.v18i1.2965","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的:因此,本荟萃分析旨在评估血清尿酸在胃肠道癌症(GI)患者中的预后价值。背景:越来越多的证据表明,高血尿酸可作为胃肠道恶性肿瘤的潜在预后指标。然而,在报告的发现中存在不一致的地方。方法:通过检索PubMed、Web of Science、Cochrane Library和Scopus等数据库,独立检索相关研究,检索截止日期为2023年10月30日。对数据的异质性进行了相关分析。根据纳入标准,我们使用报道血清/血浆尿酸预后价值的英文原始论文来确定胃肠道肿瘤患者的危险比(HR)和95%可信区间(CI)。合并风险比(hr)和95%置信区间(CIs)用于确定尿酸水平与胃肠道癌症(GI)风险的关系。不一致指数(I2)用于计算所选研究之间的异质性水平。采用Newcastle-OTTAWA量表(NOS)评价每项研究的质量。结果:本次meta分析共纳入9篇论文,共纳入95.285例患者。研究结果显示,血清尿酸与胃肠道肿瘤患者预后不良之间存在显著相关性(HR=1.477, 95% CI 1.165-1.873, P= 0.001)。此外,在亚组分析中,我们发现不同尿酸临界值(≥5mg/dl)的患者生存率较低,HR= 1.403, 95% CI=1.150-1.711, P=0.001。结论:血清尿酸水平与胃肠道癌症患者的生存结局显著相关。血清尿酸水平可能是与胃肠道癌症患者临床结果相关的有效预后标志物。鉴于本荟萃分析中纳入的研究数量少且异质性高,我们建议需要进行更全面的研究以获得更可靠的结果。
Prognostic value of circulating uric acid in gastrointestinal cancers, a systematic review and meta-analysis.
Aim: Thus, this meta-analysis was performed to assess the prognostic value of serum uric acid in patients with gastrointestinal cancers (GI).
Background: There is growing evidence that high serum uric acid may be used as a potential prognostic marker in gastrointestinal malignancies. However, there are inconsistencies in the reported findings.
Methods: Related studies were identified by searching the following databases: PubMed, Web of Science, Cochrane Library, and Scopus, independently up until 30 October 2023. Relevant analyses were carried out to deal with heterogeneity in the data. According to the inclusion criteria, we used English original papers reporting prognostic value of serum/plasma uric acid to determine hazard ratio (HR) and 95% confidence interval (CI) in patients with GI cancers. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to ascertain the association of uric acid levels with gastrointestinal cancer (GI) risk. The inconsistency index (I2) was used to calculate the level of heterogeneity among the selected studies. The quality of each study was evaluated by Newcastle-OTTAWA Scales (NOS).
Results: A total of 9 papers with 95.285 patients were included in this meta-analysis. The findings indicated a significant association between serum uric acid and poor prognosis in patients with gastrointestinal cancers (HR=1.477, 95% CI 1.165-1.873, P= 0.001). Further, in Subgroup analysis we found that patients would have poor survival rate among different cut-offs of uric acid, ≥ 5mg/dl, HR= 1.403, 95% CI=1.150-1.711, P=0.001 vs cut-off <5mg/dl, HR=1.54, 95% CI=1.140-2.063, P=0.005.
Conclusion: Serum uric acid level is significantly linked to survival outcomes in patients with gastrointestinal cancers. Serum uric acid levels may be an effective prognostic marker associated with clinical outcomes in patients with gastrointestinal cancers. Given the small number of studies included in this meta-analysis and high heterogeneity, we suggest that a more comprehensive study is required to achieve more robust results.